These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 23515752

  • 21. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
    Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
    [Abstract] [Full Text] [Related]

  • 22. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z, Gao W.
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [Abstract] [Full Text] [Related]

  • 23. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R, Zhou S, Xia B, Zhang CY, Hai P, Zhe H, Wang YY.
    BMC Cancer; 2016 Jul 18; 16():491. PubMed ID: 27431492
    [Abstract] [Full Text] [Related]

  • 24. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S.
    Cancer Sci; 2018 Oct 18; 109(10):3183-3196. PubMed ID: 30098066
    [Abstract] [Full Text] [Related]

  • 25. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y, Wu J, Yan H, Cheng Y, Wang Y, Yang Y, Deng M, Che X, Hou K, Qu X, Zou D, Liu Y, Zhang Y, Hu X.
    Pharmacol Res; 2020 Sep 18; 159():105007. PubMed ID: 32561477
    [Abstract] [Full Text] [Related]

  • 26. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 27. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 28. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun 26; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

  • 29. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
    Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM.
    Cell Death Dis; 2013 Sep 19; 4(9):e810. PubMed ID: 24052078
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.
    Cancer Res; 2013 Apr 15; 73(8):2428-34. PubMed ID: 23382048
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
    Wu DW, Chen TC, Huang HS, Lee H.
    Cell Death Dis; 2016 Jun 30; 7(6):e2290. PubMed ID: 27362807
    [Abstract] [Full Text] [Related]

  • 34. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S, Im JH, Kim WK, Choi YJ, Lee JY, Kim SK, Kim SJ, Kwon SW, Kang KW.
    Oxid Med Cell Longev; 2021 Jun 30; 2021():5428364. PubMed ID: 34367462
    [Abstract] [Full Text] [Related]

  • 35. Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
    Yang Z, Hu X, Zhang S, Zhang W, Tam KY.
    Eur J Pharmacol; 2017 Nov 15; 815():80-87. PubMed ID: 28870456
    [Abstract] [Full Text] [Related]

  • 36. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, Chen YB.
    Oncotarget; 2015 Jun 10; 6(16):14329-43. PubMed ID: 25869210
    [Abstract] [Full Text] [Related]

  • 37. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
    Jang WJ, Jung SK, Kang JS, Jeong JW, Bae MK, Joo SH, Park GH, Kundu JK, Hong YS, Jeong CH.
    Cancer Sci; 2014 Oct 10; 105(10):1245-53. PubMed ID: 25117641
    [Abstract] [Full Text] [Related]

  • 38. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
    Fu Y, Zhang Y, Lei Z, Liu T, Cai T, Wang A, Du W, Zeng Y, Zhu J, Liu Z, Huang JA.
    J Hematol Oncol; 2020 Dec 07; 13(1):169. PubMed ID: 33287873
    [Abstract] [Full Text] [Related]

  • 39. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.
    PLoS Med; 2007 Oct 07; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [Abstract] [Full Text] [Related]

  • 40. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X.
    Theranostics; 2021 Oct 07; 11(2):824-840. PubMed ID: 33391507
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.